We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BIOCORP, Diabeloop Partner on Automated Diabetes Management Devices

BIOCORP, Diabeloop Partner on Automated Diabetes Management Devices

team up
March 23, 2021

BIOCORP and Diabeloop have announced a cooperation agreement to develop new, personalized treatment devices for diabetes patients.

BIOCORP developed and sells Mallya, an intelligent sensor for insulin-injection pens that monitors doses, while Diabeloop has developed automated insulin-delivery systems, including a self-learning handset that connects to a continuous glucose-monitoring solution and insulin pump.

The agreement will combine Diabeloop’s automated solutions with BIOCORP’s insulin-pen technology.

View today's stories

Medical Devices Commercial Operations

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 21Jun

    Medical Device Reporting: Best Practices and Common Pitfalls

  • 22Jun

    Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Linear Health Sciences Gets FDA Clearance for Its Orchid Safety Release Valve

  • Roche’s Faricimab Gains UK Approval Via International Program

  • Becton Dickinson Gets FDA Clearance for Its Molecular Diagnostic Platform

  • Bayer Backs Out of $670 Million Collaboration Deal With Atara

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing